A daily pill could be as effective for weight loss as popular drugs like Wegovy and Ozempic, providing an alternative to the injectable medications. The pill, orforglipron, is also a GLP-1 drug, working in a similar way to Ozempic,

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to face off with Ozempic maker Novo Nordisk. Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.